European Archives - Page 794 of 1167 - European Medical Journal

Ten-Year Outcomes of End-Stage Kidney Disease

A comparison of dialysis and kidney transplants, based on Canadian data, has shown there are major differences in long-term outcomes between the two treatments in individuals with ESKD…

Impact of Consuming Soft Drinks Post-Exercise on Kidneys

KIDNEY function could be negatively impacted by drinking a soft drink after exercising or carrying out manual labour…

Obstructive Nephropathy Surgery Leads to Mice Kidneys Repairing Themselves

BLOCKED KIDNEYS in newborn mice can repair themselves following the surgical removal of the obstruction…

Clinical Trial Results Give Hope for Treatment of Drug-Resistant Tuberculosis

VITAMIN D could provide vital new treatment options for patients with multi-drug resistant tuberculosis (TB) according to the results of a recent clinical..

Potential Misdiagnoses of Chronic Obstructive Pulmonary Disease

The need for a revaluation of chronic obstructive pulmonary disease (COPD) diagnostic practices has been highlighted by a study investigating the records…

How safe are heat-not-burn smoking devices?

One of the latest additions to the panoply of smoking devices is the heat-not-burn (HNB) devices. These are positioned as a hybrid of traditional…

A proactive approach to patient centricity

The increasing focus on patient centricity in recent years has ensured pharmaceutical companies are far more in sync with the issues that patients’ face on a day-to-day basis than ever before; however, translating these insights into treatment improvements remains a challenge.

An entrepreneurial approach to R&D

Decline in R&D productivity levels is rapidly becoming one of the biggest challenges for the pharmaceutical industry, but what can it do?

Amgen’s Victoria Elegant on driving innovation through diversity and inclusion

Victoria Elegant, Vice President and Region Head of Medical, Amgen, shares insights on the importance of diversity in delivering innovation, pharma in the JAPAC region and what medical affairs teams across the globe can learn from China.

Lead us on, medical affairs

Perfectly positioned to bridge the gap between R&D and commercial, MA must seize their strategic position within the industry to guide the future of the function.